Osteoprotegerin diminishes advanced bone cancer pain.
Bone cancer pain most commonly occurs when tumors originating in breast, prostate, or lung metastasize to long bones, spinal vertebrae, and/or pelvis. Primary and metastatic cancers involving bone account for approximately 400,000 new cancer cases per year in the United States alone, and >70% of patients with advanced breast or prostate cancer have skeletal metastases. Whereas pain resulting from bone cancer can dramatically impact an individual's quality of life, very little is known about the mechanisms that generate and maintain this pain. To begin to define the mechanisms that give rise to advanced bone cancer pain, osteolytic 2472 sarcoma cells or media were injected into the intramedullary space of the femur of C3H/HeJ mice, and the injection hole was sealed using dental amalgam, confining the tumor cells to the bone. Twelve days after injection of 2472 tumor cells, animals showed advanced tumor-induced bone destruction of the injected femur, bone cancer pain, and a stereotypic set of neurochemical changes in the spinal cord dorsal horn that receives sensory inputs from the affected femur. Administration of osteoprotegerin, a naturally secreted decoy receptor that inhibits osteoclast maturation and activity and induces osteoclast apoptosis, or vehicle was begun at 12 days, when significant bone destruction had already occurred, and administration was continued daily until day 21. Ongoing pain behaviors, movement-evoked pain behaviors, and bone destruction were assessed on days 10, 12, 14, 17, and 21. The neurochemistry of the spinal cord was evaluated at days 12 and 21. Results indicated that osteoprotegerin treatment halted further bone destruction, reduced ongoing and movement-evoked pain, and reversed several aspects of the neurochemical reorganization of the spinal cord. Thus, even in advanced stages of bone cancer, ongoing osteoclast activity appears to be involved in the generation and maintenance of ongoing and movement-evoked pain. Blockade of ongoing osteoclast activity appears to have the potential to reduce bone cancer pain in patients with advanced tumor-induced bone destruction.
Luger
N M
NM
Neurosystems Center, Department of Orthopedic Surgery, University of Minnesota, Minneapolis, MN 55455, USA.
Honore
P
P
Sabino
M A
MA
Schwei
M J
MJ
Rogers
S D
SD
Mach
D B
DB
Clohisy
D R
DR
Mantyh
P W
PW
D000818:Animals; D001859:Bone Neoplasms / Q000150:complications* / Q000473:pathology; D004195:Disease Models, Animal; D006023:Glycoproteins / Q000494:pharmacology*; D008297:Male; D051379:Mice; D008809:Mice, Inbred C3H; D009475:Neurons, Afferent / Q000378:metabolism / Q000502:physiology; D010010:Osteoclasts / Q000187:drug effects / Q000502:physiology; D010014:Osteolysis / Q000150:complications / Q000188:drug therapy / Q000209:etiology; D053244:Osteoprotegerin; D010146:Pain / Q000188:drug therapy* / Q000209:etiology; D016760:Proto-Oncogene Proteins c-fos / Q000096:biosynthesis; D018160:Receptors, Cytoplasmic and Nuclear; D018124:Receptors, Tumor Necrosis Factor; D012513:Sarcoma, Experimental / Q000150:complications / Q000473:pathology; D013116:Spinal Cord / Q000187:drug effects / Q000473:pathology
D006023:Glycoproteins; D053244:Osteoprotegerin; D016760:Proto-Oncogene Proteins c-fos; D018160:Receptors, Cytoplasmic and Nuclear; D018124:Receptors, Tumor Necrosis Factor; C506031:Tnfrsf11b protein, mouse